The inhibition of BRD4 with BET inhibitors disrupts the transcriptional machinery at the level of super-enhancers, which are crucial for maintaining the high expression of MYC and other oncogenes in KMT2Ar leukemias. This evidence concerns the gene BRD4 and leukemia.